A detailed history of Lazard Asset Management LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 3,629 shares of ARWR stock, worth $92,793. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,629
Previous 4,065 10.73%
Holding current value
$92,793
Previous $124,000 17.74%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$27.21 - $39.48 $11,863 - $17,213
-436 Reduced 10.73%
3,629 $102,000
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $996 - $1,458
47 Added 1.17%
4,065 $124,000
Q3 2023

Nov 14, 2023

BUY
$26.2 - $36.08 $41,631 - $57,331
1,589 Added 65.42%
4,018 $107,000
Q2 2023

Aug 14, 2023

SELL
$25.16 - $41.38 $32,305 - $53,131
-1,284 Reduced 34.58%
2,429 $86,000
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $13,402 - $21,796
566 Added 17.99%
3,713 $94,000
Q4 2022

Feb 14, 2023

SELL
$28.0 - $40.56 $18,592 - $26,931
-664 Reduced 17.42%
3,147 $127,000
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $207 - $338
7 Added 0.18%
3,811 $125,000
Q2 2022

Aug 09, 2022

BUY
$27.79 - $50.61 $52,161 - $94,994
1,877 Added 97.41%
3,804 $133,000
Q1 2022

May 13, 2022

BUY
$39.62 - $69.97 $20,760 - $36,664
524 Added 37.35%
1,927 $87,000
Q4 2021

Feb 09, 2022

SELL
$58.09 - $82.51 $1.48 Million - $2.1 Million
-25,444 Reduced 94.77%
1,403 $92,000
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $1.42 Million - $2.07 Million
24,317 Added 961.15%
26,847 $1.68 Million
Q2 2021

Aug 12, 2021

BUY
$62.15 - $90.32 $154,939 - $225,167
2,493 Added 6737.84%
2,530 $209,000
Q4 2020

Feb 11, 2021

BUY
$43.82 - $85.37 $1,621 - $3,158
37 New
37 $2,000
Q1 2020

May 14, 2020

SELL
$20.56 - $63.12 $15,419 - $47,340
-750 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$28.14 - $73.01 $21,105 - $54,757
750 New
750 $47,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.71B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.